drugset / Trial / NCT01114698

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

NCT01114698

Phase 2 Terminated 12 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.

Timeline

Start
2011-03
Primary completion
2012-01
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ26489112 Small molecule 1000 mg Oral
Comparator Venlafaxine Small molecule 150 mg Oral

Indications